Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...

Full description

Bibliographic Details
Main Authors: Daniele Lavacchi, Elisa Pellegrini, Valeria Emma Palmieri, Laura Doni, Marinella Micol Mela, Fabrizio Di Maida, Amedeo Amedei, Serena Pillozzi, Marco Carini, Lorenzo Antonuzzo
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:International Journal of Molecular Sciences
Subjects:
immune checkpoint inhibitors
renal cell carcinoma
tyrosine kinase inhibitors
predictive biomarkers
Online Access:https://www.mdpi.com/1422-0067/21/13/4691

Internet

https://www.mdpi.com/1422-0067/21/13/4691

Similar Items